ArticleJournal of cell communication and signaling2026
Diagnostic potential of B-cell translocation gene 2 in IgA nephropathy: Insights from molecular mechanisms.
Article in Journal of cell communication and signaling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgA nephropathy (IgAN) is a prevalent glomerular disease characterized by IgA deposition, chronic inflammation, and fibrosis, leading to end-stage renal disease. This study explored B-cell translocation gene 2 (BTG2) as a biomarker and treatment target for IgAN progression. Through integrated expression datasets and functional analyses, BTG2 emerged as a key gene with downregulation in renal tissues of IgAN patients, showing high diagnostic accuracy. BTG2 influenced the immune microenvironment by modulating T follicular helper cells and M0 macrophages. Moreover, BTG2 overexpression mitigated IgA deposition and fibrosis, whereas its silencing exacerbated these pathological changes. The study highlights BTG2 as a promising diagnostic tool and therapeutic target, shedding light on potential treatment strategies for IgAN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.